Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 3;316(7):447.
doi: 10.1007/s00403-024-03020-1.

Antitumor activity of anlotinib in malignant melanoma: modulation of angiogenesis and vasculogenic mimicry

Qian Yang  1 , Qianqian Li  2 , Hua Fan  3
Affiliations

Antitumor activity of anlotinib in malignant melanoma: modulation of angiogenesis and vasculogenic mimicry

Qian Yang et al. Arch Dermatol Res. .

Abstract

Malignant melanoma presents a formidable challenge due to its aggressive metastatic behavior and limited response to current treatments. To address this, our study delves into the impact of anlotinib on angiogenesis and vasculogenic mimicry using malignant melanoma cells and human umbilical vein endothelial cells. Evaluating tubular structure formation, cell proliferation, migration, invasion, and key signaling molecules in angiogenesis, we demonstrated that anlotinib exerts a dose-dependent inhibition on tubular structures and effectively suppresses cell growth and invasion in both cell types. Furthermore, in a mouse xenograft model, anlotinib treatment resulted in reduced tumor growth and vascular density. Notably, the downregulation of VEGFR-2, FGFR-1, PDGFR-β, and PI3K underscored the multitargeted antitumor activity of anlotinib. Our findings emphasize the therapeutic potential of anlotinib in targeting angiogenesis and vasculogenic mimicry, contributing to the development of novel strategies for combating malignant melanoma.

Keywords: Angiogenesis; Anlotinib; Malignant melanoma; Multitargeted therapy; Therapeutic innovation; Vasculogenic mimicry.

PubMed Disclaimer

References

    1. Arnold M, Singh D, Laversanne M et al (2022) Global burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatol 158(5):495–503. https://doi.org/10.1001/jamadermatol.2022.0160 - DOI - PubMed - PMC
    1. Fania L, Didona D, Di Pietro FR et al (2021) Cutaneous squamous cell carcinoma: from pathophysiology to novel therapeutic approaches. Biomedicines 9(2):171. https://doi.org/10.3390/biomedicines9020171 - DOI - PubMed - PMC
    1. Cheng X, Wang X, Nie K et al (2021) Systematic pan-cancer analysis identifies TREM2 as an immunological and prognostic biomarker. Front Immunol 12:646523. https://doi.org/10.3389/fimmu.2021.646523 - DOI - PubMed - PMC
    1. Evidence reviews for surgical and histological excision margins for people with stage 0 to II melanoma: Melanoma: assessment and management. London: National Institute for Health and Care Excellence (NICE); July 2022.
    1. van Akkooi AC, Hauschild A, Long GV et al (2023) COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma. Future Oncol 19(30):2017–2027. https://doi.org/10.2217/fon-2023-0414 - DOI - PubMed

MeSH terms

LinkOut - more resources

-